Karolinska Development’s Chairman of the Board resigns from his position

STOCKHOLM, SWEDEN – August 20, 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its Chairman of the Board, Professor Hans Wigzell, has informed the Board that he resigns from his position for personal reasons. The Board will immediately initiate a process to appoint a new Chairman.

Hans Wigzell has been a Board member of Karolinska Development since 2006 and held the role of Chairman during the periods 2006–2013 and 2018–2020. His solid scientific knowledge, many years of experience in drug development and extensive international network have been instrumental in the company's development during the 14 years he has been engaged in the company.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB

Phone: 2, e-mail:

Fredrik Järrsten, CFO and deputy CEO, Karolinska Development AB

Phone: +46 70 496 46 28, e-mail:

TO THE EDITORS

About Karolinska Development AB



Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit

This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Viktor Drvota, at 10:30 CET on 20 August 2020.

Attachment